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Abstract
Background: Concurrent chemoradiation is becoming an increasingly popular treatment for patients with locally advanced 
head and neck cancer. The full extent of treatment related complications has not been completely documented in the litera-
ture.
Methods: We present the case of a patient treated with deﬁ  nitive intensity modulated radiation therapy and concurrent 
carboplatin and ﬂ  uorouracil for a locally advanced oral cavity and base of tongue cancer.
Results: The patient suffered acute grade 4 dermatitis and mucositis during treatment. One month after completion of treat-
ment, the patient was found to have permanent adherence of the tongue to the buccal mucosa as a result of severe scar 
tissue formation.
Conclusions: As more patients undergo chemoradiation for the treatment of locally advanced head and neck cancer, the 
full extent of treatment related complications are being identiﬁ  ed. To our knowledge, this is the ﬁ  rst report of chemoradia-
tion for head and neck cancer resulting in adherence of the tongue to the buccal mucosa.
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Introduction
A major paradigm shift has occurred over the past two decades in the treatment of locally advanced head 
and neck cancer. Although many patients were cured using the traditional approach of surgery and postop-
erative radiation, functional outcomes were often suboptimal. This led investigators to pursue aggressive 
organ preservation protocols using combined chemotherapy and radiation.
1 Chemoradiotherapy protocols 
have demonstrated equal survival rates compared to surgery while providing high rates of organ preserva-
tion and less treatment related morbidity.
2–4 Nevertheless, the toxicity from this treatment can be debilitat-
ing with a myriad of early and late effects, resulting in a deleterious impact on patient quality of life.
5–7
In this paper, we report on a 74 year old woman with a locally advanced, oral cavity and base of 
tongue (BOT) cancer treated with deﬁ  nitive intensity modulated radiation therapy (IMRT) and concur-
rent chemotherapy (5-ﬂ  uorouracil and carboplatin). During treatment, she experienced grade 4 derma-
titis and mucositis. Approximately one month after the completion of treatment, she developed 
adherence of the oral tongue to the buccal mucosa. To our knowledge, this particular toxicity has never 
been reported in the published literature.
Case Report
A 74 year old female with no signiﬁ  cant past medical history and no risk factors for head and neck 
cancer presented to the Memorial Sloan-Kettering Cancer Center in October 2005. She reported a sev-
eral month history of difﬁ  culty placing her dentures, a painful lump towards the back of the tongue and 
a 20 pound unintentional weight loss. On examination, there was a large mass replacing the entire right 
side of the tongue extending from the tip of the tongue to the vallecula with inﬁ  ltration of the right ﬂ  oor 314
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of mouth and submucosa. Biopsy of the mass 
identiﬁ  ed squamous cell carcinoma. There were 
ﬁ  xed right level II and level III lymph nodes.
An MRI demonstrated a large, enhancing mass 
involving the right oral tongue and ﬂ  oor of mouth, 
crossing midline and extending posteriorly to the 
vallecula. There were bilateral enlarged cervical 
(Fig. 1). A PET/CT scan showed no evidence of 
distant metastases.
The tumor was staged as T4aN2cM0 oral cavity 
and BOT carcinoma; due to the extensive involve-
ment of the oral cavity and BOT, it was difﬁ  cult to 
determine the epicenter of the tumor. It was deemed 
to be resectable but would require a near-total 
glossectomy, base of tongue resection, pharyngec-
tomy, laryngectomy and bilateral neck dissections. 
Furthermore, postoperative chemoradiation would 
likely be indicated for high-risk features. Given 
the anticipated morbidity of this treatment, deﬁ  ni-
tive chemoradiation was recommended. A hearing 
evaluation identiﬁ  ed high frequency hearing loss, 
precluding the use of cisplatin. Therefore, a deci-
sion was made to use three cycles of concurrent 
carboplatin (70 mg/m2) and 5-fluorouracil 
(600 mg/m2) administered every three weeks.
Radiation was delivered with a seven-ﬁ  eld, dose 
painting, split ﬁ  eld IMRT plan with primarily 
posterior beams (Fig. 2). The area of gross disease 
was prescribed 6996 cGy (2.12 cGy/fraction) and 
areas of high risk subclinical disease were 
prescribed 5940 cGy (180 cGy/fraction), all 
delivered in 33 fractions. The low neck received 
5040 cGy in 28 fractions with a single anterior 
beam. The lips were not contoured as an avoidance 
structure. Isodose curves and dose volume 
histograms were generated and reviewed. Standard 
dose constraints were met for all critical structures. 
Parotid sparing was not possible due to the size of 
the mass. The mean dose to the oral cavity was 
unusually high (7444 cGy) due to the size and 
location of the tumor. The maximum PTV point 
dose was 7912 cGy (113% of prescription).
A percutaneous gastrostomy tube (PEG) was 
placed prior to initiation of therapy for nutritional 
support during treatment. On 12/5/05 (day 1), the 
patient initiated radiation and chemotherapy. The 
second cycle of chemotherapy was administered 
as scheduled on day 22. During the fourth week of 
treatment, the patient developed grade 2 mucositis. 
She continued on treatment without major incident 
until the start of week 6 when she presented to 
clinic with severe full thickness ulcerations around 
the lips with spontaneous bleeding. In the oral 
cavity, there were confluent ulcerations with 
bleeding (Fig. 3) consistent with grade 4 dermatitis 
and mucositis. After a nine day treatment break, 
her symptoms subsided and she resumed radiation. 
She completed the remainder of radiation without 
difﬁ  culty on 2/1/06. The third cycle of chemotherapy 
was withheld. The patient had a slow decline in 
oral intake throughout treatment. By week six, she 
was entirely dependent on the PEG.
She was seen for her ﬁ  rst followup visit ﬁ  ve 
weeks after completion of treatment. Her lips and 
perioral skin were completely healed (Fig. 4). She 
reported dysphagia and dysarthria. She was toler-
ating a liquid diet but was using the PEG for 
supplementation. On inspection of the oral cavity, 
the right side of the tongue was adhered to the right 
buccal mucosa (Fig. 5). Clinically, there was no 
evidence of disease. An MRI several weeks later 
showed no evidence of disease.
Figure 1. Pretreatment MRI. Axial fast spin-echo T2-weighted image 
with fat saturation at the level of the primary tumor and upper 
neck.315
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The consensus from the Head and Neck Tumor 
Board at MSKCC was to pursue a course of close 
observation. A lysis of adhesions was planned if 
there was no disease recurrence for at least six 
months. Unfortunately, within several months the 
patient developed widespread metastases. She died 
of progressive pulmonary disease in November. 
At the time of death, she was free loco-regional 
recurrence.
Discussion
Aggressive chemoradiation regimens for the treat-
ment of locally advanced head and neck cancer 
have been gaining popularity as a growing body 
of literature suggests equal survival between surgi-
cal and nonsurgical approaches.
1–4 Intuitively, 
organ preservation should result in a better quality 
of life (QOL) by preserving breathing, swallowing 
and communicating functions. However, QOL in 
Figure 2. Isodose curves of an inverse IMRT plan displayed on the axial plane at the level of the oral cavity.
Figure 3. Phorograph at the start of week of six of treatment, just prior to receiving a treatment break.316
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these patients is often compromised as a result of 
poor organ function. Several studies have shown 
that patients treated with organ preservation pro-
tocols often experience signiﬁ  cant late toxicity 
resulting in severe physical, emotional and psy-
chological effects and relatively low QOL scores.
6–8 
In a study from UCLA, researchers found equal 
QOL scores between patients who underwent 
radical surgery and postoperative radiation versus 
combined chemoradiation.
9
As more patients receive and survive chemora-
diation for head and neck cancers, a better appre-
ciation of the long-term side effects associated with 
this treatment will be gained. In this paper, we 
report a unique complication in a patient treated 
with chemoradiation for a large of base of tongue 
carcinoma. During treatment, the patient experi-
enced grade 4 mucositis and dermatitis. Such 
toxicity is known to occur in a small percentage of 
patients receiving concurrent chemoradiation. 
Shortly after the completion of treatment, however, 
she developed a complication that, to our 
knowledge, has not yet been described in the 
literature: adherence of the tongue to the buccal 
mucosa as a result of scar tissue.
Traditionally, radiation side effects have been 
categorized as either early or late and for many 
years the two were thought to be unrelated entities 
developing via different mechanisms. Recently, 
however, “consequential late effects” have been 
described.
10–14 These were ﬁ  rst observed with the 
introduction of aggressive treatment regimens 
using altered fractionation and combined modality 
protocols.
10–15 In these situations, acute reactions 
fail to heal completely and persist into the “late” 
period.
We believe that the adherence of the tongue to 
the buccal mucosa described in the is report is 
analogous to pharyngoesophageal strictures, which 
are known to occur in up to 50% of patients 
receiving head and neck radiation.
6 A study from 
the University of Miami showed that in patients 
receiving chemoradiation for head and neck cancer, 
those who experienced severe mucositis during 
Figure 4. Photograph at the ﬁ  rst followup visit ﬁ  ve weeks after 
completion of treatment.
Figure 5. Photograph of the oral cavity at the ﬁ  rst followup visit ﬁ  ve 
weeks after completion of treatment. The right oral tongue is adhered 
to the right buccal mucosa.317
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treatment were more likely to develop esophageal 
strictures.
15 Pharyngoesophageal strictures result 
from ﬁ  brosis, narrowing and muscle dysfunction. 
These strictures are usually detected several 
months after the completion of treatment. We 
hypothesize that the “stricture” described in this 
report resulted from a similar mechanism but was 
detected sooner than traditional strictures because 
of its anatomic location. The oral cavity is easily 
examined and adhesions in the oral cavity were 
immediately visible at the time of ﬁ  rst followup. 
This is in contrast to esophageal strictures, which 
usually are not detected until a GI workup is pur-
sued in patients with persistent dysphagia.
There is currently no consensus as to which 
chemotherapy regimen should be used in 
conjunction with deﬁ  nitive radiation as head to 
head comparisons have not yet been performed. 
Recent meta-analyses have shown that platinum-
based chemotherapy is more effective than non-
platinum containing regimens and that single agent 
therapy is equivalent to multi-agent therapy.
1,16 
Many institutions, including our own, use three 
cycles of cisplatin (100 mg/m
2) administered every 
three weeks as the standard regimen. Trials 
with carboplatin and 5-FU have demonstrated 
comparable outcomes and toxicity compared to 
other regimens. However, 5-FU is known to cause 
mucositis and some consider this regimen to be 
more toxic. For non-platinum candidates, we 
consider Erbitux as an effective alternative at our 
institution. The obvious advantage to using 
concurrent Erbitux is that it does not increase the 
rate of mucositis compared to radiation alone and 
does not have a deleterious effect on QOL.
17 It is 
possible that the use of 5-FU in this patient 
contributed to her complication. We now try to 
avoid using this regimen in patients who will 
receive a high oral cavity dose.
The use of IMRT as a technique to deliver high 
doses of radiation to target volumes and minimize 
the dose to nearby organs at risk has resulted in 
less long-term treatment related morbidity 
and enhanced quality of life for head and 
neck patients.
18–21 One potential pitfall of 
IMRT, however, is that it often results in dose 
inhomogeneity and can lead to areas within the 
target or immediately outside of it receiving more 
than the prescription dose. In order to minimize 
this, it is critical to carefully evaluate dose volume 
histograms and volumetric dose distributions 
which will identify any “hot spots” in the PTV or 
immediately outside of it. In this particular report, 
the maximum point dose was 113% of prescription 
and there were two small areas in the oral cavity 
which received 111% (7750 cGy) (Fig. 2). These 
areas, however, did not correlate anatomically with 
the site of ﬁ  brosis on the right buccal mucosa. 
Therefore, we feel it is unlikely that the in-
homogeneity of the plan contributed to the toxic-
ity. Nevertheless, the value of using IMRT in this 
case, when normal tissue sparing was not 
attempted, is debatable. Using parallel opposed 
beams may have resulted in a more homogeneous 
dose distribution. In addition, due to the use of 
multiple beams with IMRT, it is not unusual to 
have “dose dumping” outside of the target area. 
This results in a higher volume of surrounding 
tissue receiving low dose radiation than with con-
ventional radiation. For example, the lips in this 
case received a higher dose than would be expected 
with a conventional plan where the lips would 
have been completely out of the ﬁ  eld. Therefore, 
IMRT should only be used for cases in which 
normal tissue sparing is the feasible. As a result 
of this event, we now often contour the lips as an 
avoidance structure when using IMRT to treat oral 
cavity and large oropharynx tumors.
Our preference has been to use dose-painting 
in conjunction with IMRT. With this technique, the 
area of gross disease receives a larger dose per 
fraction (2.12 Gy) and areas of subclinical disease 
receive lower doses (1.8 Gy). We have used this 
fractionation to treat multiple head and neck sites 
at our institution for several years with excellent 
tumor control and without unexpected toxic-
ity.
22–23 Altered fractionation results in higher rates 
of toxicity than standard fractionation. When 
altered fractionation is used with concurrent che-
motherapy, toxicity is quite severe. Perhaps dose 
painting IMRT (which is a form of altered frac-
tionation) with concurrent chemotherapy also 
increases toxicity. More time will be needed to 
determine the full extent of late effects with this 
regimen. It is unlikely that fraction size contributed 
to this particular toxicity.
We have not routinely used amifostine in 
patients being treated with concurrent IMRT and 
chemotherapy. Although amifostine has been 
proven to reduce the rate of acute and late xerosto-
mia,
24 its ability to decrease mucositis is conﬂ  ict-
ing.
25, 26 Perhaps in cases such as this with large 
target volumes, a radiation protector such as ami-
fostine should be considered.318
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In conclusion, this report contributes to the 
growing body of literature describing the acute and 
late effects associated with head and neck radio-
therapy. As more patients are treated with aggres-
sive organ preservation protocols, it is important 
to characterize the morbidity of treatment and to 
study its impact on quality of life. We must not 
forget that the goal of such regimens is organ func-
tion, not just organ preservation. Careful attention 
should be given to radiation technique, dose, 
fractionation and concurrent systemic therapy to 
minimize potential toxicity.
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